TranSenda to Develop “Cortex” Performance Management System to Improve Clinical Trial Performance
News Jun 19, 2009
TranSenda International, LLC has announced that it is developing a new solution, Cortex, designed to improve an organization’s ability to manage a clinical trial’s performance.
Based upon patent-pending ClinBUS® data interchange technology already in use in TranSenda’s Office-Smart solutions, Cortex will enable organizations to leverage the power of access to centralized operational data from all applications used across all clinical studies.
For years the industry has struggled with an increasingly fragmented environment of disconnected clinical applications, sites and partners. TranSenda’s Cortex, with its ClinBUS technology, represents a breakthrough in managing and controlling studies within a common environment - independent of study data formats and clinical trial applications.
With the Cortex clinical trial management performance system, sponsors and Clinical Research Organizations (CROs) will benefit from real-time connectivity across complex partner networks and enterprise environments.
With this data now centralized, analysis is enhanced because ClinBUS technology is optimized to make data available in Microsoft® Office SharePoint Server (MOSS). Data can be easily controlled, communicated and coordinated between people and applications using MOSS.
Current industry practice relies on custom data connections between applications which are specific to each trial. By connecting all applications and all trials in a single information system, Cortex creates sustainable access to important operational data.
Cortex accomplishes this by standardizing the exchange of clinical trial management data and its semantics in a centralized server. Standardizing common operational data also facilitates interoperability between various clinical trial applications, including legacy Clinical Trial Management Systems (CTMS). Using ClinBUS data interchange technology, Cortex is also compatible with CDISC ODM data types.
Cortex is also designed to facilitate codeless customization by users with SharePoint® experience and by Microsoft Independent Software Vendors (ISVs). This feature enables the extension and customization of clinical processes at a fraction of the cost and time of conventional development environments.
Cortex basically unleashes access to operational information across applications and trials and allows it to be used in Microsoft’s Office System for the creation of configurable dashboards, specialized reports and custom workflow.
Not only does Cortex unleash operational information to allow organizations to transform it into valuable knowledge, Cortex also enables a new level of “centralized” study management.
An example of a centralized application that can take advantage of the Cortex environment is TranSenda’s Office-Smart Clinical Payment Manager. Site payment information that works on operational data maintained in ClinBUS from diverse CTMS and EDC systems could be managed centrally, helping ensure bottom-line study and meeting upcoming regulatory requirements for disclosure of items of value to healthcare professionals.
Value-added SharePoint web parts to assist with reporting study enrollment, subject completion, Case Report Form (CRF) progress, and clinical site payment tracking are also planned for the upcoming release. Commercial availability will be announced at a later date.
Antimalarial Drugs Could Offer Clinical Benefit to Cancer PatientsNews
Antimalarial drugs chloroquine and hydroxychloroquine could find another use as cancer treatments, according to a new clinical study published in ecancermedicalscience.READ MORE
Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line TreatmentNews
The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.READ MORE
Diabetes Drug Could Be Re-purposed to Help End Transplant RejectionNews
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs.READ MORE
Comments | 0 ADD COMMENT
3rd Annual NGS Data Analysis and Informatics Conference
Feb 08 - Feb 09, 2018
3rd Annual Genome Editing & Engineering Conference
Feb 08 - Feb 09, 2018